Literature DB >> 27138963

Refined comorbidity index based on dimensionality of comorbidity for use in studies of health-related quality of life.

Huang-Tz Ou1, Chung-Ying Lin2, Steven R Erickson3, Rajesh Balkrishnan4.   

Abstract

PURPOSE: To refine two subscales of the health-related quality of life comorbidity index (HRQoL-CI) into a single index measure.
METHODS: The 2010 and 2012 Medical Expenditure Panel Surveys were utilized as development and validation datasets, respectively. The least absolute shrinkage and selection operator was applied to select important comorbidity candidates associated with HRQoL. Exploratory factor analysis and confirmatory factor analysis (CFA) were used to assess dimensionality in comorbidity. Statistical weights were derived based on standardized factor loadings from CFA and regression coefficients from the model predicting HRQoL. Prediction errors and model R(2) values were compared between HRQoL-CI and Charlson CI (CCI).
RESULTS: Eighteen comorbid conditions were identified. CFA models indicated that the second-order multidimensional comorbidity structure had a better fit to the data than did the first-order unidimensional structure. The predictive performance of the refined scale under a multidimensional structure utilizing statistical weights outperformed the original scale and CCI in terms of average prediction error and R(2) in the prediction models (R(2) values from refined scale model are 0.25, 0.30, and 0.28 versus those from CCI of 0.10, 0.09, and 0.06 for general health, SF-6D, and EQ-5D, respectively).
CONCLUSION: The dimensionality of comorbidity and the weight scheme significantly improved the performance of the refined HRQoL-CI. The refined single HRQoL-CI measure appears to be an appropriate and valid instrument specific for risk adjustment in studies of HRQoL. Future research that validates the refined scales for different cultures, age groups, and healthcare settings is warranted.

Entities:  

Keywords:  Comorbidity index; Dimensionality; Factor analysis; Health-related Quality of life; Least absolute shrinkage and selection operator; Risk prediction model

Mesh:

Year:  2016        PMID: 27138963     DOI: 10.1007/s11136-016-1306-6

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  32 in total

1.  A new comorbidity index: the health-related quality of life comorbidity index.

Authors:  Bhramar Mukherjee; Huang-Tz Ou; Fei Wang; Steven R Erickson
Journal:  J Clin Epidemiol       Date:  2010-12-13       Impact factor: 6.437

2.  US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

Authors:  James W Shaw; Jeffrey A Johnson; Stephen Joel Coons
Journal:  Med Care       Date:  2005-03       Impact factor: 2.983

3.  Health-related quality of life in cancer survivors between ages 20 and 64 years: population-based estimates from the Behavioral Risk Factor Surveillance System.

Authors:  Lisa C Richardson; Phyllis A Wingo; Matthew M Zack; Hatice S Zahran; Jessica B King
Journal:  Cancer       Date:  2008-03-15       Impact factor: 6.860

4.  Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases.

Authors:  M van den Akker; F Buntinx; J F Metsemakers; S Roos; J A Knottnerus
Journal:  J Clin Epidemiol       Date:  1998-05       Impact factor: 6.437

5.  Comorbidity and functional status are independent in older cancer patients.

Authors:  M Extermann; J Overcash; G H Lyman; J Parr; L Balducci
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

6.  The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus.

Authors:  M H Kaplan; A R Feinstein
Journal:  J Chronic Dis       Date:  1974-09

7.  Risk adjustment in outcome assessment: the Charlson comorbidity index.

Authors:  W D'Hoore; C Sicotte; C Tilquin
Journal:  Methods Inf Med       Date:  1993-11       Impact factor: 2.176

8.  Health related quality of life outcomes after total hip and knee arthroplasties in a community based population.

Authors:  C A Jones; D C Voaklander; D W Johnston; M E Suarez-Almazor
Journal:  J Rheumatol       Date:  2000-07       Impact factor: 4.666

9.  Validation of a combined comorbidity index.

Authors:  M Charlson; T P Szatrowski; J Peterson; J Gold
Journal:  J Clin Epidemiol       Date:  1994-11       Impact factor: 6.437

10.  Comorbidity of chronic diseases in general practice.

Authors:  F G Schellevis; J van der Velden; E van de Lisdonk; J T van Eijk; C van Weel
Journal:  J Clin Epidemiol       Date:  1993-05       Impact factor: 6.437

View more
  1 in total

1.  Development of a core outcome set for multimorbidity trials in low/middle-income countries (COSMOS): study protocol.

Authors:  Jan R Boehnke; Rusham Zahra Rana; Jamie J Kirkham; Louise Rose; Gina Agarwal; Corrado Barbui; Alyssa Chase-Vilchez; Rachel Churchill; Oscar Flores-Flores; John R Hurst; Naomi Levitt; Josefien van Olmen; Marianna Purgato; Kamran Siddiqi; Eleonora Uphoff; Rajesh Vedanthan; Judy Wright; Kath Wright; Gerardo A Zavala; Najma Siddiqi
Journal:  BMJ Open       Date:  2022-02-16       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.